HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

5.615

-0.005-0.09%

Volume:2.47M

Turnover:13.94M

Market Cap:2.20B

PE:-8.74

High:5.715

Open:5.620

Low:5.560

Close:5.620

52wk High:77.000

52wk Low:4.940

Shares:391.00M

HK Float Shares:386.00M

Volume Ratio:0.92

T/O Rate:0.64%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.643

ROE:-125.57%

ROA:-44.55%

PB:7.04

PE(LYR):-8.74

PS:-164.11

Loading ...

Overview Company News Filings

PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative

PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver

Bulletin Express

PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung

BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million

PegBio Trims Losses in 2025

MT Newswires Live

PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings

Bulletin Express

PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates

Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln

THOMSON REUTERS

PegBio Wins China Approval for PB-119 Vepinetide Injection###

PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million

BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China

PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment

PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million

Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln

THOMSON REUTERS

Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/02565/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":5.615,"timestamp":1789099500006,"preClose":5.62,"halted":0,"volume":2471050,"delay":0,"changeRate":-0.0008896797153024721,"floatShares":386000000,"shares":391000000,"eps":-0.6427182905312684,"marketStatus":"Noon Closed","change":-0.005,"latestTime":"09-11 12:05:00","open":5.62,"high":5.715,"low":5.56,"amount":13935904,"amplitude":0.02758,"askPrice":5.615,"askSize":1450,"bidPrice":5.61,"bidSize":5350,"shortable":3,"etf":0,"ttmEps":-0.9974894382748479,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789102800000},"marketStatusCode":3,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.62,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.921649,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":386000000,"roa":"-44.55%","roe":"-125.57%","lyrEps":-0.642723,"volumeRatio":0.921649,"shares":391000000,"dividePrice":0,"high":5.715,"amplitude":0.02758,"preClose":5.62,"low":5.56,"week52Low":4.94,"pbRate":"7.04","psRate":"-164.11","week52High":77,"institutionHeld":0,"latestPrice":5.615,"committee":0.573529,"eps":-0.6427233305103353,"divideRate":0,"volume":2471050,"delay":0,"ttmEps":-0.997497260249051,"open":5.62,"prevYearClose":69,"prevWeekClose":5.735,"prevMonthClose":5.495,"prevQuarterClose":5.33,"fiveDayClose":5.735,"twentyDayClose":6.23,"sixtyDayClose":6.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-09-10","current":-5.629132,"percent":0.983871,"low":-87.782868,"twenty":-72.540901,"median":-49.876406,"eighty":-11.23576,"high":-5.557418,"avg":-42.593424,"sd":28.530571,"marketCap":2197934409},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-29","current":-13.590249,"twenty":-73.716985,"median":-61.274827,"eighty":-19.064042,"marketCap":3375119921},{"date":"2026-06-05","current":-12.579887,"twenty":-73.438012,"median":-61.206433,"eighty":-18.597951,"marketCap":3128732256},{"date":"2026-06-12","current":-11.565594,"twenty":-73.352041,"median":-60.919795,"eighty":-17.056006,"marketCap":2874522760},{"date":"2026-06-18","current":-9.622776,"twenty":-73.31105,"median":-60.791238,"eighty":-14.753422,"marketCap":2397391091},{"date":"2026-06-26","current":-7.824338,"twenty":-73.278872,"median":-60.512398,"eighty":-13.899973,"marketCap":1939813998},{"date":"2026-07-03","current":-8.984958,"twenty":-73.271235,"median":-60.431019,"eighty":-13.561687,"marketCap":2229221732},{"date":"2026-07-10","current":-11.252888,"twenty":-73.25947,"median":-60.210807,"eighty":-13.050401,"marketCap":2788482623},{"date":"2026-07-17","current":-10.458113,"twenty":-73.235067,"median":-60.159469,"eighty":-12.830773,"marketCap":2600758687},{"date":"2026-07-24","current":-10.046967,"twenty":-73.215248,"median":-60.107782,"eighty":-12.739192,"marketCap":2499074889},{"date":"2026-07-31","current":-8.411523,"twenty":-73.183292,"median":-59.862622,"eighty":-12.522041,"marketCap":2096250611},{"date":"2026-08-07","current":-10.298244,"twenty":-73.061453,"median":-59.675079,"eighty":-12.306772,"marketCap":2571426822},{"date":"2026-08-14","current":-9.745542,"twenty":-72.966779,"median":-59.367669,"eighty":-11.991332,"marketCap":2436500244},{"date":"2026-08-21","current":-9.169953,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"marketCap":2297662750},{"date":"2026-08-28","current":-5.766342,"twenty":-72.790068,"median":-56.898206,"eighty":-11.368021,"marketCap":2225310817},{"date":"2026-09-04","current":-5.809614,"twenty":-72.647581,"median":-53.43223,"eighty":-11.296065,"marketCap":2242909936},{"date":"2026-09-10","current":-5.685446,"twenty":-72.540901,"median":-49.876406,"eighty":-11.23576,"marketCap":2197934409}],"updateTime":1789101717161},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106026379","title":"PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1106026379","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106026379?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:10","pubTimestamp":1775041812,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that Mr. Zou Xinglong has resigned from his positions as Joint Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","399441","BK4585","XBI","BK4588","BK4581","BK1161","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100737065","title":"PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1100737065","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100737065?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:04","pubTimestamp":1775041467,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. has disclosed a senior management change effective 1 April 2026. Joint Company Secretary, Authorised Representative and Process Agent Mr. Chow Shing Lung will step down, citing no...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624289597","title":"PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2624289597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624289597?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:02","pubTimestamp":1775041346,"startTime":"0","endTime":"0","summary":"PegBio appointed Kwok Yan Ting Jennis as joint company secretary, authorized representative, process agent effective April 1, 2026.Kwok is senior manager, Entity Solutions at Computershare Hong Kong Investor Services with more than 12 years’ experience in corporate governance, company secretarial practice, regulatory compliance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL9mQGfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK1161","CPU.AU","BK7033","02565","BK7157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775537","title":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775537?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:49","pubTimestamp":1774262958,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 MillionMarch 23 (Reuters) - PegBio Co Ltd 2565.HK:FY LOSS ATTRIBUTABLE RMB208.4 MILLIONFurther company coverage: 2565.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621779352","title":"PegBio Trims Losses in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779352?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:00","pubTimestamp":1774256439,"startTime":"0","endTime":"0","summary":"PegBio  booked 208.4 million yuan in attributable loss for 2025, narrowing from 283.4 million yuan in 2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.55 yuan, compared with 0.77 yuan in the prior year.The firm did not generate any revenue during the year or in 2024.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191587925","title":"PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587925?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255349,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B, 02565) released its audited results for the year ended 31 December 2025. Financial Performance   • Loss for the year narrowed 26.4% to RMB208.55 million, versus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180038614","title":"PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=1180038614","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180038614?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255342,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced its annual results for the period ending December 31, 2025. The Group recorded other net income of RMB189,000 and research and development expenses of RMB50.387 million....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","BK4581","BK4585","BK4588","02565","XBI","BK1161","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621469775","title":"Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621469775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621469775?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:32","pubTimestamp":1774254727,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775455","title":"PegBio Wins China Approval for PB-119 Vepinetide Injection###","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775455?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254699,"startTime":"0","endTime":"0","summary":"Pegbio said its PB-119 product received marketing approval from China’s National Medical Products Administration in November 2025, enabling a shift from development to commercialization planning.The company expects PB-119 to begin commercial sales in 1H 2026, positioning it to become Pegbio’s first revenue-generating product.Pegbio is pursuing a partnership-based commercialization approach in mainland China after a prior marketing collaboration for PB-119 was terminated in June 2025.The company reported no revenue from PB-119 as of the announcement date and ended 2025 with CNY 467.5 million in cash and cash equivalents to support launch execution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9pF429:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775453","title":"PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775453","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775453?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254694,"startTime":"0","endTime":"0","summary":"PegBio published an annual results announcement for the year ended Dec. 31, 2025.Loss from operations narrowed 26.73% to RMB205.77 million, and loss for the year narrowed 26.4% to RMB208.55 million.Basic and diluted loss per share improved 28.57% to RMB0.55, while the company reported no revenue from product sales.Total assets rose more than 1.7x to RMB599.23 million, and cash and cash equivalents rose more than 1.7x to RMB467.54 million.PB-119 received marketing approval from China’s NMPA in November 2025, and PegBio expects commercial sales to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7sY1nP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620741213","title":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741213?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:34","pubTimestamp":1773718440,"startTime":"0","endTime":"0","summary":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry** China-based PegBio Co 2565.HK shares jump as much as 20.3% to HK$65.15, set for biggest one-day pct rise since August 15, 2025 ** Innovative therapies developer's stock hit the highest point since March 9** PegBio said it has entered into an exclusive commercialization collaboration with Shanghai Tenry Pharmaceutical for the company's core product Paidakang for treatment of type 2 diabetes in China ** Tenry Pharmaceutical will pay royalty totaling HK$140 million  to the company - Co** YTD, stock down 17.6%, while Hang Seng Biotech Index .HSBIO climbs 3.8%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N40503X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306701.USD","BK4588","01276","BK1606","BK4585","HK0000165453.HKD","BK1191","HK0000306685.HKD","LU2543165471.USD","BK1197","LU1023057109.AUD","BK1161","02696","00874","01428","BK1521","HK0000320223.HKD","LU0359202008.SGD","06688","BK1515","VXUS","LU0359201612.USD","LU0359201885.HKD","BK1147","02565"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619463298","title":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463298","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463298?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:54","pubTimestamp":1773665640,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland ChinaMarch 16  - PegBio Co Ltd 2565.HK:ENTERS EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND CHINAAGGREGATE COMMERCIALIZATION SALES TARGET OVER RMB10 BILLION, ROYALTY ABOUT HK$140 MILLIONFurther company coverage: 2565.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172606217","title":"PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1172606217","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172606217?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658483,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced the signing of a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical Co., Ltd. for the commercialization of its core product, Paidakang, in Mainland...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","BK1161","XBI","BK4588","02565","399441","BK1191","BK1574","BK4581","01477","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547714","title":"PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547714?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658231,"startTime":"0","endTime":"0","summary":"PegBio entered a strategic cooperation agreement with Tenry Pharmaceutical for the commercialization of Paidakang in mainland China. Under the arrangement, Tenry will handle exclusive commercialization and promotion activities for the product in mainland China. The companies set a cumulative sales target of more than CNY 10 billion for Paidakang under the commercialization plan. Tenry will pay PegBio royalties totaling about HKD 140 million, which are expected to be paid within the current year. Sales revenue for Paidakang in mainland China will be recognized by PegBio, while PegBio retains intellectual property and overseas market interests for the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7S60br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547904","title":"Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547904?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619454200","title":"Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454200?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":117,"code":"91000000","status":"200"}]}}